Clinical Trial

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer overall and live longer without the cancer growing or spreading than people who receive chemotherapy.
Protocol Amendment History 38 amendments
This ClinicalTrials.gov record has been amended 38 times since 2025-04-07; most recent amendment 2026-07-15.
Status change: Not Yet Recruiting → Recruiting 2025-05-16
Trial Details
NCT Number NCT06925737
Lead Sponsor Merck Sharp & Dohme LLC
Collaborators: Daiichi Sankyo
Conditions Prostate Cancer, Prostatic Neoplasms
Enrollment 1,440 participants
Start Date 2025-05-13
Primary Completion 2028-06-26 (estimated)
Study Completion 2031-01-06 (estimated)
Updated on ClinicalTrials.gov 2026-08-14